Hartrampf PE, Weinzierl FX, Seitz AK, Kubler H, et al. Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy. Prostate 2022;82:1406-1412.
PMID: 35860909